129 related articles for article (PubMed ID: 30719396)
21. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Quek L; David MD; Kennedy A; Metzner M; Amatangelo M; Shih A; Stoilova B; Quivoron C; Heiblig M; Willekens C; Saada V; Alsafadi S; Vijayabaskar MS; Peniket A; Bernard OA; Agresta S; Yen K; MacBeth K; Stein E; Vassiliou GS; Levine R; De Botton S; Thakurta A; Penard-Lacronique V; Vyas P
Nat Med; 2018 Aug; 24(8):1167-1177. PubMed ID: 30013198
[TBL] [Abstract][Full Text] [Related]
22. IDH1/IDH2 Inhibition in Acute Myeloid Leukemia.
Cerchione C; Romano A; Daver N; DiNardo C; Jabbour EJ; Konopleva M; Ravandi-Kashani F; Kadia T; Martelli MP; Isidori A; Martinelli G; Kantarjian H
Front Oncol; 2021; 11():639387. PubMed ID: 33898313
[TBL] [Abstract][Full Text] [Related]
23. The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia.
Zhuang X; Pei HZ; Li T; Huang J; Guo Y; Zhao Y; Yang M; Zhang D; Chang Z; Zhang Q; Yu L; He C; Zhang L; Pan Y; Chen C; Chen Y
Front Oncol; 2022; 12():931462. PubMed ID: 35814406
[TBL] [Abstract][Full Text] [Related]
24. An evaluation of enasidenib for the treatment of acute myeloid leukemia.
Del Principe MI; Paterno G; Palmieri R; Maurillo L; Buccisano F; Venditti A
Expert Opin Pharmacother; 2019 Nov; 20(16):1935-1942. PubMed ID: 31454277
[No Abstract] [Full Text] [Related]
25. Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters.
Morell A; Budagaga Y; Vagiannis D; Zhang Y; Laštovičková L; Novotná E; Haddad A; Haddad M; Portillo R; Hofman J; Wsól V
Arch Toxicol; 2022 Dec; 96(12):3265-3277. PubMed ID: 35972551
[TBL] [Abstract][Full Text] [Related]
26. Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML.
Jasra S; Kazemi M; Shah N; Chen J; Fehn K; Wang Y; Mantzaris I; Kornblum N; Sica A; Bachier L; Goldfinger M; Gritsman K; Braunschweig I; Steidl U; Shastri A; Verma A
Exp Hematol Oncol; 2021 Jan; 10(1):1. PubMed ID: 33397455
[TBL] [Abstract][Full Text] [Related]
27. Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications.
Lee S; Urman A; Desai P
Leuk Lymphoma; 2019 Nov; 60(11):2635-2645. PubMed ID: 30958073
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis.
Chen X; Xing H; Xie X; Kou L; Li J; Li Y
Clin Epigenetics; 2023 Jul; 15(1):113. PubMed ID: 37434249
[TBL] [Abstract][Full Text] [Related]
29. Phospholipid metabolic adaptation promotes survival of IDH2 mutant acute myeloid leukemia cells.
Morishima T; Takahashi K; Chin DWL; Wang Y; Tokunaga K; Arima Y; Matsuoka M; Suda T; Takizawa H
Cancer Sci; 2024 Jan; 115(1):197-210. PubMed ID: 37882467
[TBL] [Abstract][Full Text] [Related]
30. Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials.
Montesinos P; Fathi AT; de Botton S; Stein EM; Zeidan AM; Zhu Y; Prebet T; Vigil CE; Bluemmert I; Yu X; DiNardo CD
Blood Adv; 2024 May; 8(10):2509-2519. PubMed ID: 38507688
[TBL] [Abstract][Full Text] [Related]
31. Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations.
Buege MJ; DiPippo AJ; DiNardo CD
Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29882807
[TBL] [Abstract][Full Text] [Related]
32. Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics.
Golub D; Iyengar N; Dogra S; Wong T; Bready D; Tang K; Modrek AS; Placantonakis DG
Front Oncol; 2019; 9():417. PubMed ID: 31165048
[TBL] [Abstract][Full Text] [Related]
33. Treatment for Relapsed/Refractory Acute Myeloid Leukemia.
Thol F; Heuser M
Hemasphere; 2021 Jun; 5(6):e572. PubMed ID: 34095756
[TBL] [Abstract][Full Text] [Related]
34. Integrating Full Bayesian Inference and Student's t-Distribution Method for Enhanced Outlier Handling in Caffeine Population Pharmacokinetics: Assessing Drug-Drug Interactions with Enasidenib in Relapsed or Refractory AML and MDS Patients.
Cheng Y; Du S; Hu H; Wang X; Carayannopoulos L; Li Y
J Clin Pharmacol; 2024 Jul; 64(7):866-877. PubMed ID: 38478303
[TBL] [Abstract][Full Text] [Related]
35. Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients.
Grassi S; Guerrini F; Ciabatti E; Puccetti R; Salehzadeh S; Metelli MR; Di Vita A; Domenichini C; Caracciolo F; Orciuolo E; Pelosini M; Mazzantini E; Rossi P; Mazziotta F; Petrini M; Galimberti S
Cancers (Basel); 2020 Jun; 12(7):. PubMed ID: 32629801
[TBL] [Abstract][Full Text] [Related]
36. Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.
Pasquier F; Lecuit M; Broutin S; Saada S; Jeanson A; Penard-Lacronique V; de Botton S
Drugs Today (Barc); 2020 Jan; 56(1):21-32. PubMed ID: 32055803
[TBL] [Abstract][Full Text] [Related]
37. New and emerging therapies for acute myeloid leukaemia.
Davis JR; Benjamin DJ; Jonas BA
J Investig Med; 2018 Dec; 66(8):1088-1095. PubMed ID: 30127098
[TBL] [Abstract][Full Text] [Related]
38. Assessment of CYP-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Cheng Y; Wang X; Ghosh A; Pu J; Carayannopoulos LN; Li Y
J Clin Pharmacol; 2024 Apr; ():. PubMed ID: 38563070
[TBL] [Abstract][Full Text] [Related]
39. Enasidenib Approved for AML, but Best Uses Unclear.
Cancer Discov; 2017 Oct; 7(10):OF4. PubMed ID: 28818952
[TBL] [Abstract][Full Text] [Related]
40. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
Upadhyay VA; Brunner AM; Fathi AT
Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
